Related Experiment Video
Updated: Jun 22, 2026
14:34
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
QT as a safety biomarker in drug development
D J Whellan1, C L Green, J P Piccini
1Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. david.whellan@jefferson.edu
Clinical Pharmacology and Therapeutics
|May 29, 2009
Summary
Ensuring new drug cardiovascular safety is crucial for regulators and patients. The primary concern during drug development is preventing ventricular arrhythmias that can lead to sudden cardiac death.
Area of Science:
- Pharmacology
- Cardiology
- Drug Safety
Background:
- Cardiovascular safety is a critical concern for new drug development.
- Stakeholders include the pharmaceutical industry, FDA, physicians, and patients.
- Concerns encompass vasculature, valvular tissue, myopathies, and electrophysiology.
Purpose of the Study:
- To highlight the paramount importance of cardiovascular safety in drug development.
- To identify the most pressing cardiac safety concern during drug evaluation.
Main Methods:
- Review of existing drug development safety protocols.
- Analysis of reported adverse cardiovascular events associated with new drugs.
- Assessment of regulatory guidelines for cardiovascular risk assessment.
Main Results:
- Ventricular arrhythmias leading to sudden death represent the most significant cardiovascular risk.
- Other concerns include vascular, valvular, and muscular effects.
- Comprehensive safety evaluation is essential prior to drug approval.
Conclusions:
- Mitigating the risk of drug-induced ventricular arrhythmias is a top priority.
- Rigorous cardiovascular safety testing is indispensable for new drug development.
- Protecting patients from sudden cardiac death is a key objective.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...